T010015 Chemical Structure

All Products are stable to be shipped at room temperature, unless otherwise specified.
Pack SizeQuantityPrice (USD)Sub Total
1mg
$ 195.000.0
2.5mg
$ 425.000.0
5mg
$ 800.000.0
10mg
$ 1515.000.0
Exact Weight Packaging
$ 95.000.0
Total$ 0.0
  • Request another packsize ? Click here.
  • Inventory Status : Currently Back Ordered - Please Request Lead Time
  • Ships On :
T010015

Bulk Order Request for T010015

#Pack SizeUnitQuantity
1.
2.
3.
4.
5.

Product Description

Catalogue NumberT010015
Chemical NameTaxol E
Synonyms(αR,βS)-α-Hydroxy-β-[[(2S)-2-methyl-1-oxobutyl]amino]benzenepropanoic Acid (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester; [2aR-[2aα,4β,4aβ,6β,9α[αR*,βS*(S*)],11α,12α,12aα,12bα]]- α-Hydroxy-β-[(2-methyl-1-oxobutyl)amino]benzenepropanoic Acid 6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester; [2aα,4β,4aβ,6β,9α[αR*,βS*(S*)],11α,12α,12aα,12bα]]-‡7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete Benzenepropanoic Acid Deriv.; Paclitaxel Impurity R;
CAS Number158948-96-0
Molecular FormulaC₄₅H₅₅NO₁₄
Molecular Weight833.92
Category Standards; Pharmaceutical/API Drug Impurities/Metabolites;
ApplicationsTaxol E is an impurity of Paclitaxel (P132500); an antineoplastic. Used in the study of structure and function of microtubles into tubulin. Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is a mitotic inhibitor used in cancer chemotherapy.
ReferencesLetourneau, P.C., et al.: J. Cell Biol., 98, 1355 (1984); Manfredi, J.J., et al.: Pharmacol. Ther., 25, 83 (1984); Danesi, R., et al.: Mol. Pharmacol., 47, 1106 (1995); Markman, M., et al.: Expert. Opin. Pharmacother., 3, 755 (2002); Stone, G.W., et al.: N. Engl. J. Med., 350, 221 (2004)